Get the Stockscreener App
19.66
0.82%
+0.16
After Hours:
19.70
0.04
+0.20%
GeneDx Holdings Corp stock is currently priced at $19.66, with a 24-hour trading volume of 716.73K.
It has seen a +0.82% increased in the last 24 hours and a +108.04% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $19.65 pivot point. If it approaches the $20.74 resistance level, significant changes may occur.
Previous Close:
$19.50
Open:
$19.47
24h Volume:
716.73K
Market Cap:
$514.13M
Revenue:
$202.57M
Net Income/Loss:
$-175.77M
P/E Ratio:
-0.5529
EPS:
-35.5597
Net Cash Flow:
$-185.86M
1W Performance:
+77.44%
1M Performance:
+108.04%
6M Performance:
+980.22%
1Y Performance:
+142.18%
1D Range:
$19.09
$21.71
52W Range:
$1.16
$21.71
GeneDx Holdings Corp Stock (WGS) Company Profile
Name
GeneDx Holdings Corp
Sector
Industry
Phone
800 298 6470
Address
North Tower, 8th Floor 333 Ludlow Street, Stamford
GeneDx Holdings Corp Stock (WGS) Latest News
GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
GeneDx Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire Inc.
GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
GlobeNewswire Inc.
Take the Zacks Approach to Beat the Market: Virtu, Coinbase, General Mills in Focus
Zacks Investment Research
GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024
GlobeNewswire Inc.
Here's Why GENEDX HOLDINGS (WGS) Could be Great Choice for a Bottom Fisher
Zacks Investment Research
GeneDx Holdings Corp Stock (WGS) Financials Data
GeneDx Holdings Corp (WGS) Revenue 2024
WGS reported a revenue (TTM) of $202.57 million for the quarter ending December 31, 2023, a -13.69% decline year-over-year.
GeneDx Holdings Corp (WGS) Net Income 2024
WGS net income (TTM) was -$175.77 million for the quarter ending December 31, 2023, a +67.98% increase year-over-year.
GeneDx Holdings Corp (WGS) Cash Flow 2024
WGS recorded a free cash flow (TTM) of -$185.86 million for the quarter ending December 31, 2023, a +44.27% increase year-over-year.
GeneDx Holdings Corp (WGS) Earnings per Share 2024
WGS earnings per share (TTM) was -$7.4397 for the quarter ending December 31, 2023, a +86.34% growth year-over-year.
About GeneDx Holdings Corp
Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.
0.06%
4.53%
Cap:
|
Volume (24h):